Low-Dose Aspirin for Preeclampsia Prevention
Yes, initiate low-dose aspirin 81 mg daily in high-risk pregnant women starting between 12-16 weeks of gestation (optimally before 16 weeks) and continue until delivery to prevent preeclampsia. This recommendation is supported by multiple major guidelines and reduces maternal morbidity and mortality from preeclampsia 1.
Who Should Receive Aspirin
High-Risk Factors (One or More = Start Aspirin)
- History of preeclampsia, especially early-onset (<34 weeks) or in multiple pregnancies
- Multifetal gestation (twins, triplets)
- Chronic hypertension
- Type 1 or type 2 diabetes
- Renal disease
- Autoimmune disease (e.g., lupus, antiphospholipid syndrome)
Moderate-Risk Factors (Two or More = Start Aspirin)
- First pregnancy
- Maternal age ≥35 years or older
- BMI >30 kg/m²
- Family history of preeclampsia (mother or sister)
- Pregnancy interval >10 years
- Personal history factors (prior adverse pregnancy outcomes)
The USPSTF, ACOG, WHO, NICE, American Heart Association, and American Academy of Family Physicians all recommend this approach 1, 2.
Dosing Specifics
Use 81 mg daily. While international guidelines vary slightly (60-150 mg range), the most recent high-quality evidence supports 81 mg as the optimal dose 1. A 2026 randomized controlled trial directly comparing 162 mg versus 81 mg found no difference in preventing preterm preeclampsia or preeclampsia with severe features (14.1% vs 17.1%, RR 0.83, P=0.4), but the 162 mg group had significantly more placental abruptions (8 cases vs 0, P=0.013) 3. Network meta-analysis suggests 80-100 mg/day provides optimal effectiveness while minimizing side effects 4.
Timing
Start between 12-16 weeks of gestation, optimally before 16 weeks. Earlier initiation appears more effective. Continue daily until delivery 1, 2. The ASPRE trial demonstrated that aspirin started between 11-14 weeks reduced preterm preeclampsia by 62% 5.
Safety Profile
Low-dose aspirin at 81 mg daily has a favorable safety profile when used for preeclampsia prophylaxis 1, 2. The evidence shows:
- No significant increase in postpartum hemorrhage
- No significant increase in small for gestational age infants
- No significant increase in intrauterine growth restriction
- Low likelihood of serious maternal or fetal complications 4, 2
Critical caveat: Higher doses (162 mg) may increase placental abruption risk 3. The FDA label warns about aspirin use in the last 3 months of pregnancy for general indications, but this does not apply to low-dose prophylactic use under medical supervision 6.
Common Pitfalls to Avoid
- Don't wait too long to start: Initiation after 16 weeks is less effective. Screen for risk factors at the first prenatal visit.
- Don't use higher doses without evidence: The 162 mg dose offers no additional benefit and may increase harm 3, 7.
- Don't overlook moderate-risk factors: Two or more moderate-risk factors warrant aspirin prophylaxis 2, 8.
- Don't forget adherence: Effectiveness depends on daily use throughout pregnancy. Counsel patients on the importance of consistent adherence 3.
Implementation Strategy
Use a systematic checklist at the first prenatal visit to screen all pregnant patients for the 16 recognized risk factors 8. This reduces the chance of inadvertently overlooking candidates who would benefit from prophylaxis. Document the screening and decision-making process clearly.
Universal aspirin for all pregnant women is not supported by current evidence and would unnecessarily expose low-risk women to treatment with limited absolute benefit 9. Targeted prophylaxis following first-trimester risk stratification remains the evidence-based approach.